Metagenomi, Inc. Files Amendment No. 2 to S-1 Registration Statement

Ticker: MGX · Form: S-1/A · Filed: Feb 5, 2024 · CIK: 1785279

Metagenomi, Inc. S-1/A Filing Summary
FieldDetail
CompanyMetagenomi, Inc. (MGX)
Form TypeS-1/A
Filed DateFeb 5, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$15.00, $17.00
Sentimentneutral

Complexity: moderate

Sentiment: neutral

Topics: IPO, S-1 Filing, Metagenomi, SEC Filing, Biotechnology

TL;DR

<b>Metagenomi, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing preparations for a public offering.</b>

AI Summary

Metagenomi, Inc. (MGX) filed a Amended IPO Registration (S-1/A) with the SEC on February 5, 2024. Metagenomi, Inc. filed an amendment (S-1/A) to its registration statement on February 5, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. Metagenomi, Inc. is located at 5959 Horton Street, 7th Floor, Emeryville, California. The filing is related to the Securities Act of 1933. The company was formerly known as Metagenomi Technologies, LLC.

Why It Matters

For investors and stakeholders tracking Metagenomi, Inc., this filing contains several important signals. This S-1/A filing signifies that Metagenomi is moving forward with its plans to become a publicly traded company, which could provide access to capital for research and development. The amendment suggests updates or clarifications to the initial registration statement, potentially addressing SEC comments or providing new information relevant to potential investors.

Risk Assessment

Risk Level: low — Metagenomi, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step for an IPO and does not contain new financial performance data or significant business updates that would alter the risk profile.

Analyst Insight

Monitor future filings for the pricing and effectiveness of the S-1 registration statement to assess the company's IPO progress and valuation.

Key Numbers

  • 2024-02-05 — Filing Date (Date the amendment was filed)
  • 333-276413 — Registration Number (SEC registration number for the offering)
  • 2836 — SIC Code (Standard Industrial Classification Code)
  • 832735153 — IRS Number (IRS Employer Identification No.)

Key Players & Entities

  • Metagenomi, Inc. (company) — Registrant name
  • Metagenomi Technologies, LLC (company) — Former company name
  • Delaware (jurisdiction) — State of incorporation
  • Brian C. Thomas, Ph.D. (person) — Chief Executive Officer
  • Goodwin Procter LLP (company) — Legal counsel
  • Davis Polk & Wardwell LLP (company) — Legal counsel

Forward-Looking Statements

  • Metagenomi, Inc. will complete its initial public offering (IPO) (Metagenomi, Inc.) — medium confidence, target: Q2 2024
  • The stock will trade on a major exchange (e.g., Nasdaq or NYSE) (Metagenomi, Inc.) — high confidence, target: Q2 2024

FAQ

When did Metagenomi, Inc. file this S-1/A?

Metagenomi, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on February 5, 2024.

What is a S-1/A filing?

A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by Metagenomi, Inc. (MGX).

Where can I read the original S-1/A filing from Metagenomi, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Metagenomi, Inc..

What are the key takeaways from Metagenomi, Inc.'s S-1/A?

Metagenomi, Inc. filed this S-1/A on February 5, 2024. Key takeaways: Metagenomi, Inc. filed an amendment (S-1/A) to its registration statement on February 5, 2024.. The company is incorporated in Delaware and its fiscal year ends on December 31.. Metagenomi, Inc. is located at 5959 Horton Street, 7th Floor, Emeryville, California..

Is Metagenomi, Inc. a risky investment based on this filing?

Based on this S-1/A, Metagenomi, Inc. presents a relatively low-risk profile. The filing is an amendment to a registration statement, which is a standard procedural step for an IPO and does not contain new financial performance data or significant business updates that would alter the risk profile.

What should investors do after reading Metagenomi, Inc.'s S-1/A?

Monitor future filings for the pricing and effectiveness of the S-1 registration statement to assess the company's IPO progress and valuation. The overall sentiment from this filing is neutral.

How does Metagenomi, Inc. compare to its industry peers?

Metagenomi operates in the biotechnology sector, focusing on biological products.

Are there regulatory concerns for Metagenomi, Inc.?

The filing is made under the Securities Act of 1933, which governs the registration of securities.

Industry Context

Metagenomi operates in the biotechnology sector, focusing on biological products.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

  1. Track the SEC's review process for the S-1 registration statement.
  2. Analyze future amendments for updated financial information and risk factors.
  3. Monitor for the effective date and pricing of the proposed public offering.

Key Dates

  • 2024-02-05: Filing of Amendment No. 2 to S-1 Registration Statement — Indicates progress in the IPO process.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating updates or corrections rather than a new initial filing.

Filing Stats: 4,443 words · 18 min read · ~15 pages · Grade level 15.5 · Accepted 2024-02-05 06:11:22

Key Financial Figures

  • $15.00 — l public offering price will be between $15.00 and $17.00 per share. Prior to this o
  • $17.00 — fering price will be between $15.00 and $17.00 per share. Prior to this offering, th

Filing Documents

Risk Factors

Risk Factors 18 Special Note Regarding Forward-Looking Statements 90 Reorganization 92

Use of Proceeds

Use of Proceeds 94 Dividend Policy 95 Capitalization 96

Managements Discussion and Analysis of Financial Condition and Results of Operations

Managements Discussion and Analysis of Financial Condition and Results of Operations 101

Business

Business 129 Management 227

Executive Compensation

Executive Compensation 237 Director Compensation 249 Certain Relationships and Related Person Transactions 251 Principal Stockholders 255

Description of Capital Stock

Description of Capital Stock 258 Shares Eligible for Future Sale 264 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders 266

Underwriting

Underwriting 270 Legal Matters 284 Experts 284 Changes in Independent Registered Public Accounting Firm 284 Where You Can Find More Information 285 Index to Consolidated Financial Statements F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. i Table of Contents For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. Market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms, or other independent sources that we believ

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.